{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:27:49Z","timestamp":1792549669290,"version":"4.5.0"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1038\/s41582-026-01215-w","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:50:20Z","timestamp":1778068220000},"page":"329-331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Plasma biomarkers for Alzheimer disease: the road from laboratory results to clinical practice"],"prefix":"10.1038","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4061-0837","authenticated-orcid":false,"given":"Charlotte E.","family":"Teunissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Argonde C.","family":"van Harten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"1215_CR1","doi-asserted-by":"publisher","first-page":"e70828","DOI":"10.1002\/alz.70828","volume":"21","author":"S Pahlke","year":"2025","unstructured":"Pahlke, S. et al. Blood-based biomarkers for detecting Alzheimer\u2019s disease pathology in cognitively impaired individuals within specialized care settings: a systematic review and meta-analysis. Alzheimers Dement. 21, e70828 (2025).","journal-title":"Alzheimers Dement."},{"key":"1215_CR2","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-024-02988-7","volume":"30","author":"CR Jack Jr","year":"2024","unstructured":"Jack, C. R. Jr et al. Revised criteria for the diagnosis and staging of Alzheimer\u2019s disease. Nat. Med. 30, 2121\u20132124 (2024).","journal-title":"Nat. Med."},{"key":"1215_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s13195-025-01925-1","volume":"18","author":"MIJ Honey","year":"2025","unstructured":"Honey, M. I. J. et al. Individualized prediction of clinical progression to dementia using plasma biomarkers in non-demented elderly. Alzheimers Res. Ther. 18, 4 (2025).","journal-title":"Alzheimers Res. Ther."},{"key":"1215_CR4","doi-asserted-by":"publisher","first-page":"e2545862","DOI":"10.1001\/jamanetworkopen.2025.45862","volume":"8","author":"C Trieu","year":"2025","unstructured":"Trieu, C. et al. Longitudinal blood-based biomarkers and clinical progression in subjective cognitive decline. JAMA Netw. Open 8, e2545862 (2025).","journal-title":"JAMA Netw. Open"},{"key":"1215_CR5","doi-asserted-by":"publisher","first-page":"8216","DOI":"10.1002\/alz.14184","volume":"20","author":"MM Mielke","year":"2024","unstructured":"Mielke, M. M. et al. Recommendations for clinical implementation of blood-based biomarkers for Alzheimer\u2019s disease. Alzheimers Dement. 20, 8216\u20138224 (2024).","journal-title":"Alzheimers Dement."},{"key":"1215_CR6","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/alz.12316","volume":"17","author":"O Hansson","year":"2021","unstructured":"Hansson, O. et al. The Alzheimer\u2019s Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \u03b2 and tau. Alzheimers Dement. 17, 1575\u20131582 (2021).","journal-title":"Alzheimers Dement."},{"key":"1215_CR7","doi-asserted-by":"publisher","first-page":"e70752","DOI":"10.1002\/alz.70752","volume":"21","author":"IMW Verberk","year":"2025","unstructured":"Verberk, I. M. W. et al. Evidence-based standardized sample handling protocol for accurate blood-based Alzheimer\u2019s disease biomarker measurement: results and consensus of the Global Biomarker Standardization Consortium. Alzheimers Dement. 21, e70752 (2025).","journal-title":"Alzheimers Dement."},{"key":"1215_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13195-026-01979-9","volume":"18","author":"S Vigneswaran","year":"2026","unstructured":"Vigneswaran, S. et al. Real-world diagnostic performance of blood-based biomarkers for Alzheimer\u2019s disease: robust performance except after stroke and high charlson comorbidity index. Alzheimers Res. Ther. 18, 59 (2026).","journal-title":"Alzheimers Res. Ther."},{"key":"1215_CR9","first-page":"e70003","volume":"16","author":"RZ Rousset","year":"2024","unstructured":"Rousset, R. Z. et al. Performance of plasma p-tau217 and NfL in an unselected memory clinic setting. Alzheimers Dement. 16, e70003 (2024).","journal-title":"Alzheimers Dement."},{"key":"1215_CR10","first-page":"e70186","volume":"17","author":"T Claessen","year":"2025","unstructured":"Claessen, T. et al. General practitioners\u2019 perspectives on blood biomarkers for Alzheimer\u2019s disease. Alzheimers Dement. 17, e70186 (2025).","journal-title":"Alzheimers Dement."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01215-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01215-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01215-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T12:03:07Z","timestamp":1780574587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-026-01215-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1215"],"URL":"https:\/\/doi.org\/10.1038\/s41582-026-01215-w","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"6 May 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.E.T. has research contracts with Acumen, ADx Neurosciences, AC-Immune, Alamar, Aribio, Axon Neurosciences, Beckman-Coulter, BioConnect, Bioorchestra, Brainstorm Therapeutics, C2N Diagnostics, Celgene, Cognition Therapeutics, Danaher, EIP Pharma, Eisai, Eli Lilly, Fujirebio, Instant Nano Biosensors, Merck, Muna, Nitrase Therapeutics, Novo Nordisk, Olink, PeopleBio, Quanterix, Roche, Sysmex, Toyama, Vaccinex and Vivoryon. She is editor-in-chief of\n                      Alzheimer Research and Therapy\n                      , and serves on the editorial boards of\n                      Molecular Neurodegeneration\n                      ,\n                      Alzheimer\u2019s & Dementia\n                      ,\n                      Neurology: Neuroimmunology & Neuroinflammation\n                      ,\n                      Medidact Neurologie\/Springer\n                      , and serves on committees to define guidelines for cognitive disturbances and acute neurology in the Netherlands. She has consultancy\/speaker contracts for Aribio, Biogen, Beckman-Coulter, Cognition Therapeutics, Danaher, Eisai, Eli Lilly, Janssen, Merck, Neurogen Biomarking, Nordic Biosciences, Novo Nordisk, Novartis, Olink, Quanterix, Roche, Sanofi and Veravas. A.C.vH.\u2019s research is supported by Stichting Alzheimer Nederland (WE.06\u20102021\u201006) and the ADDF. A.C.vH is a recipient of TAP-dementia, a ZonMw-funded project (#10510032120003) in the context of the Dutch National Dementia Strategy, and of AlzTest\/Trinitas Dx, a PPS grant from Health Holland. She received consultancy fees (paid to her institution) from Eli Lilly in 2024.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}